Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS)

被引:56
作者
Katayama, S. [1 ]
Moriya, T. [2 ]
Tanaka, S. [3 ,4 ]
Tanaka, S. [3 ,4 ]
Yajima, Y. [2 ]
Sone, H. [5 ]
Iimuro, S. [6 ]
Ohashi, Y. [6 ]
Akanuma, Y. [7 ]
Yamada, N. [5 ]
机构
[1] Saitama Med Univ, Sch Med, Dept Endocrinol & Diabet, Moroyama, Saitama 3500495, Japan
[2] Kitasato Univ, Sch Med, Dept Diabet Endocrinol & Metab, Kanagawa, Japan
[3] Kyoto Univ, Translat Res Ctr, Kyoto, Japan
[4] Tokyo Univ Sci, Fac Engn Course, Dept Management Sci, Tokyo 162, Japan
[5] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 305, Japan
[6] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Tokyo, Japan
[7] Asahi Life Fdn, Inst Adult Dis, Tokyo, Japan
关键词
Blood pressure; Diabetic nephropathy; Glycaemic control; Progression; Remission; Smoking; ALBUMIN EXCRETION; NEPHROPATHY; RISK;
D O I
10.1007/s00125-010-2025-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to determine the transition rate and factors associated with the progression of normo- and low microalbuminuria to diabetic nephropathy (overt proteinuria). For 8 years we prospectively observed 1,558 Japanese patients with type 2 diabetes mellitus whose basal urinary albumin:creatinine ratio (UACR) had been measured as < 17.0 mg/mmol at entry. The incidence of nephropathy (UACR > 33.9 mg/mmol) was determined by measuring UACR twice a year. Progression to nephropathy occurred in 74 patients. The annual transition rate was 0.67%, and was substantially higher for the low-microalbuminuric group than for the normoalbuminuric group (1.85% and 0.23%, respectively; hazard ratio for the low-microalbuminuric group 8.45, p < 0.01). The hazard ratio for an HbA(1c) of 7-9% or a parts per thousand yen9% was 2.72 (p < 0.01) or 5.81 (p < 0.01) relative to HbA(1c) < 7.0%, respectively. In comparison with individuals with a systolic blood pressure (SBP) of < 120 mmHg, the hazard ratios for patients with an SBP of 120-140 mmHg or a parts per thousand yen140 mmHg were 2.31 (p = 0.06) and 3.54 (p < 0.01), respectively. Smoking also affected progression to proteinuria (hazard ratio 1.99, p < 0.01). In contrast, 30.3% of the low-microalbuminuric group returned to normoalbuminuria (i.e. were in remission). These results suggest that if patients with type 2 diabetes mellitus are receiving treatment from diabetologists for hyperglycaemia and hypertension when they are in the early stages of nephropathy (i.e. normo- or low microalbuminuria), their rate of transition to proteinuria is considerably lowered, and that differentiating patients with low microalbuminuria from those with high microalbuminuria might be clinically useful. UMIN Clinical Trials Registry C000000222 The study was funded by the Ministry of Health, Labour and Welfare, Japan.
引用
收藏
页码:1025 / 1031
页数:7
相关论文
共 21 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]  
[Anonymous], J JPN HEMODIALYSIS S
[3]  
[Anonymous], DIABETES RES CLIN PR
[4]   Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes [J].
Araki, S ;
Haneda, M ;
Sugimoto, T ;
Isono, M ;
Isshiki, K ;
Kashiwagi, A ;
Koya, D .
DIABETES, 2005, 54 (10) :2983-2987
[5]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[6]   The need for early predictors of diabetic nephropathy risk - Is albumin excretion rate sufficient? [J].
Caramori, ML ;
Fioretto, P ;
Mauer, M .
DIABETES, 2000, 49 (09) :1399-1408
[7]   Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes - An Asian perspective from the RENAAL study [J].
Chan, JCN ;
Wat, NMS ;
So, WY ;
Lam, KSL ;
Chua, CT ;
Wong, KS ;
Morad, Z ;
Dickson, TZ ;
Hille, D ;
Zhang, ZX ;
Cooper, ME ;
Shahinfar, S ;
Brenner, BM ;
Kurokawa, K .
DIABETES CARE, 2004, 27 (04) :874-879
[8]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[9]   THE EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON DIABETIC NEPHROPATHY [J].
LEWIS, EJ ;
HUNSICKER, LG ;
BAIN, RP ;
ROHDE, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (20) :1456-1462
[10]  
Lui SF, 1999, Hong Kong J Nephrol, V1, P53